Biotech entity
Protagonist Therapeutics is most often covered alongside Johnson & Johnson, which appears in 2 of these 3 stories. pharma accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. Each story carries 2 original sources on average, compared with 3.4 for the broader beat in this window.
Last mentioned: Jun 14, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Protagonist Therapeutics is most often covered alongside Johnson & Johnson, which appears in 2 of these 3 stories. pharma accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. Each story carries 2 original sources on average, compared with 3.4 for the broader beat in this window. Across a 110-day span, the pace is roughly 0.2 stories per week. Their average consequence score of 6 runs below the beat's 6.1 for that window. Protagonist Therapeutics appears in 3 tracked Biotech stories published from February 25, 2026 through June 14, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 400 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Protagonist Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Quarterly Earnings
Expected announcement of financial results and pipeline updates for PTGX and OEZVY.
JNJ-2113 Phase 3 Progress
Johnson & Johnson advances oral peptide JNJ-2113 into pivotal trials.
Takeda Partnership
Protagonist signs a global licensing agreement for rusfertide with $300M upfront.
Protagonist Therapeutics has transitioned from binary clinical risk to execution risk, with ICOTYDE's FDA approval and rusfertide's Priority Review. Backed by $620 million in cash, the company's validated peptide platform and royalty-based revenue model offer a compelling biotech investment thesis.
Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity.
Protagonist Therapeutics has seen its share price skyrocket by 120% following significant clinical and regulatory milestones, yet a major institutional investor has disclosed a $170 million exit. This divergence highlights a classic 'sell the news' moment or strategic rebalancing amidst a period of high valuation for the peptide-based drug developer.
Source: fool.com · finance.yahoo.com
Protagonist Therapeutics is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
